The inaugural season of the Gomezgil Yaspik Data Science Laboratory marks the beginning of a new chapter for for Bowdoin.
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacksNDA includes positive data from ...